1. Hoessly GF, Olivecrona H. Report on 280 cases of verified parasagittal meningioma. J Neurosurg. 1955; 12:614–626.
Article
2. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985; 62:18–24.
Article
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114:97–109.
Article
4. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol. 2005; 31:141–149.
Article
5. Ojemann SG, Sneed PK, Larson DA, et al. Radiosurgery for malignant meningioma: results in 22 patients. J Neurosurg. 2000; 93:Suppl 3. 62–67.
Article
6. Buetow MP, Buetow PC, Smirniotopoulos JG. Typical, atypical, and misleading features in meningioma. Radiographics. 1991; 11:1087–1106.
Article
7. Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L. Gamma Knife surgery for benign meningioma. J Neurosurg. 2007; 107:325–336.
Article
8. Nanda A, Bir SC, Konar S, et al. Outcome of resection of WHO Grade II meningioma and correlation of pathological and radiological predictive factors for recurrence. J Clin Neurosci. 2016; 31:112–121.
Article
9. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015; 17:Suppl 4. iv1–iv62.
Article
10. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002; 4:278–299.
Article
11. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg. 2004; 101:210–218.
Article
12. Lim YS, Kim MK, Park BJ, Kim TS, Lim YJ. Long term clinical outcomes of malignant meningiomas. Brain Tumor Res Treat. 2013; 1:85–90.
Article
13. Harris AE, Lee JY, Omalu B, Flickinger JC, Kondziolka D, Lunsford LD. The effect of radiosurgery during management of aggressive meningiomas. Surg Neurol. 2003; 60:298–305. discussion 305.
14. Jung HW, Yoo H, Paek SH, Choi KS. Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. Neurosurgery. 2000; 46:567–574. discussion 574-5.
Article
15. Kallio M, Sankila R, Hakulinen T, Jääskeläinen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery. 1992; 31:2–12.
Article
16. Chamberlain MC. Treatment of meningioma, including in cases with no further surgical or radiotherapy options. Oncology (Williston Park). 2015; 29:369–371.
17. Marosi C, Hassler M, Roessler K, et al. Meningioma. Crit Rev Oncol Hematol. 2008; 67:153–171.
Article
18. Gondi V, Tome WA, Mehta MP. Fractionated radiotherapy for intracranial meningiomas. J Neurooncol. 2010; 99:349–356.
Article
19. van Alkemade H, de Leau M, Dieleman EM. Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol. 2012; 14:658–666.
Article
20. Klinger DR, Flores BC, Lewis JJ, et al. Atypical meningiomas: recurrence, reoperation, and radiotherapy. World Neurosurg. 2015; 84:839–845.
Article
21. Moon HS, Jung S, Jang WY, Jung TY, Moon KS, Kim IY. Intracranial Meningiomas, WHO Grade II: Prognostic Implications of Clinicopathologic Features. J Korean Neurosurg Soc. 2012; 52:14–20.
Article
22. Adegbite AB, Khan MI, Paine KW, Tan LK. The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg. 1983; 58:51–56.
Article
23. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957; 20:22–39.
Article
24. Giombini S, Solero CL, Morello G. Late outcome of operations for supratentorial convexity meningiomas. Report on 207 cases. Surg Neurol. 1984; 22:588–594.
Article
25. de Vries J, Wakhloo AK. Repeated multifocal recurrence of grade I, grade II, and grade III meningiomas: regional multicentricity (primary new growth) or metastases? Surg Neurol. 1994; 41:299–305.
Article
26. Borovich B, Doron Y, Braun J, et al. Recurrence of intracranial meningiomas: the role played by regional multicentricity. Part 2: Clinical and radiological aspects. J Neurosurg. 1986; 65:168–171.
Article
27. Nabors LB, Portnow J, Ammirati M, et al. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014; 12:1517–1523.
28. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015; 17:116–121.
Article
29. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012; 109:63–70.
Article
30. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008; 113:2146–2151.
Article
31. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007; 69:969–973.
Article
32. Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014; 16:829–840.
Article